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Primeiro relato da administração oral de metadona em cavalos
normais para o gene de resistência múltipla às drogas (MDR1)
Cláudio Corrêa Natalini1, Nadia Crosignani1 & Renata Lehn Linardi2
ABSTRACT
Opioids are potent analgesics and are believed to be the best choice for moderate and severe nociceptive pain.
Investigating all the possible administration route options for pain management in the different animal species is warranted in
horses as systemic administration of these drugs in horses is difficult. In this study the authors describe for the first time in the
literature the administration of methadone orally to MDR1 genotipically normal horses. Twelve adult healthy horses (6 females
and 6 males) were studied. Horses randomly received one of the doses of methadone (0.1, 0.2, and 0.4mg/kg) per os, which was
administered using a 60cc syringe containing 30ml of corn syrup The results showed all doses produced plasma levels com-
patible to analgesic plasma levels in human beings. The authors conclude that methadone is absorbed when orally administered
in horses at doses of 0.1, 0.2, and 0.4 mg.kg-1. It does not produce excitement, sedation, nor undesirable side effects in healthy
horses. Further studies are necessary in order to establish clinical guidelines for oral methadone as an alternative for pain mana-
gement in the horse.
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RESUMO
Os derivados opióides são analgésicos potentes e acredita-se os fármacos de escolha para tratamento da dor nociceptiva
moderada ou severa. A investigação de todas as opções de vias de administração deve ser garantida no eqüino em razão das
dificuldades do uso sistêmico destes fármacos nesta espécie. Neste estudo, os autores descrevem pela primeira vez na literatura
a administração de metadona oral em cavalos genotipicamente normais para o gene MDR1. Foram estudados 12 eqüinos
adultos (6 machos e 6 fêmeas). Os cavalos receberam aleatoriamente uma das doses de metadona (0.1, 0.2, and 0.4 mg.kg-1) per
os, que foram administradas utilizando-se uma seringa de 60cc contendo 30ml de xarope de milho. Os resultados demonstraram
que doses variáveis de 0.1, 0.2, e 0.4 mg.kg-1 produzem concentrações plasmáticas similares as concentrações analgésicas
obtidas em seres humanos. Estas doses não produzem excitação, sedação ou efeitos colaterais indesejáveis em eqüinos hígidos.
Estudos futuros são necessários para se estabelecer as diretrizes para o uso clínico de metadona oral como alternativa para o
controle da dor no cavalo.
Descritores: farmacocinética, metadona, cavalos, MDR1.
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INTRODUCTION
Pain management is advancing continuously
in veterinary medicine. In equine medicine, it has been
shown a relevant clinical importance in shortening
and improving recovery of animals in trauma, for sur-
gical patients, and in the postoperative period [1,3,11,
13]. However, the restriction of some currently availa-
ble analgesic agents due to limited efficacy and risk of
undesirable side effects impairs in providing an effec-
tive analgesia for acute or prolonged pain in horses [1,3].
Opioids the most effective analgesic known,
are recognized to be able to treat moderate to severe
pain, persistent or chronic pain, and neuropathic pain
as well [7]. However, opioid drugs may induce central
nervous system (CNS) excitation, respiratory depres-
sion, decrease of gastrointestinal motility, and increase
of locomotor activity when used alone systemically
in horses [5].
Methadone is an opioid which has high oral
bioavailability (>70%) and long elimination half-life
(>20 hours) in human beings [9]. Oral methadone has
been widely studied in human medicine as an alter-
native route to systemic administration of opioids.
Strongly recommended as elective treatment for can-
cer pain, oral methadone is associated with minimum
or few intensive side effects in people [2]. Methadone
hydrochloride is a synthetic µ-opioid receptor agonist
(OP3 agonist) approximately equipotent to morphine
in terms of analgesia [2]. Unlike other opioid drugs,
methadone is also an N-methyl-D-aspartate (NMDA)
receptor antagonist and functions as a norepinephrine-
reuptake inhibitor. These particular characteristics may
enhance the analgesic efficacy of methadone when
compared to other therapeutic drugs [12].
The pharmacokinetics and pharmacodynamics
of methadone are a complex process and still not com-
pletely understood especially in the horse. In a single
study of intravenous methadone administered to horses
individual variation was similar to humans [8].
Considering the high analgesic efficacy of oral
methadone reported in people and the lack of infor-
mation regarding pharmacokinetics of oral opioids
in horses, the purpose of this study was to determine
the pharmacokinetic of methadone administered orally
to horses.
MATERIAL AND METHODS
Twelve adult healthy horses (6 females and 6
males) were studied. Weighing from 443kg to 577kg
(499kg±21), horses were considered free of pain due
to physical evaluation. All animals had an oral biopsy
performed in order to determine their status regarding
the MDR1 gene according to a technique previously
described [10].
Horses randomly received one of the doses of
methadone1 (0.1, 0.2, and 0.4 mg.kg-1) per os, which
was administered using a 60cc syringe containing
30ml of corn syrup. Horses were not fasted before
methadone administration. Blood samples were collec-
ted through a 14-gauge catheter previously placed on
the left jugular vein in order to measure the concen-
tration of methadone in the serum of horses. Blood
(10 ml) was collected during 24 hours, before (0) and
after oral administration, at 15 and 30 minutes, 1, 2,
3, 4, 5, 6, 9, 12, and 24 hours to complete evaluation.
Methadone serum concentrations were quan-
tified using Gas Chromatography/Mass Spectrometry
(GC/MS) analysis performed by Agilent Technologies
6890 Series GC System with a 5973 MS Detector with
electron impact ionization2. Chromatographic data
were processed using the Agilent ChemStation soft-
ware3. Serum concentrations were determined by pro-
ducing a calibration curve using the peak area ratios
of the analyte (methadone, 294 m/z) to the internal
standard (methadone-d3, 297 m/z). Results were statis-
tically compared with ANOVA tests and Bonferroni
comparison test when p<0.05.
RESULTS
No evidence of sedation, excitation or other
undesirable side effect was observed in the horses
during 24 hours of study. All three doses used (0.1,
0.2, 0.4 mg/kg) showed similar curve response. The
mean peak of methadone ranged between 30 and 60
minutes, and the lowest dose (0.1mg.kg-1) produced
significantly lower serum concentration from 15 to 120
minutes. After 360 minutes of administration of any
of the three doses, no methadone serum levels were
detected (Figure 1).
DISCUSSION
The highest detected concentration of metha-
done (30.93ng/ml) after administration of the lowest
dose, 0.1mg/kg, was similar to the minimal therapeutic
concentration of methadone for acute pain in human
beings (33ng/ml) [6]. Interesting enough, low or none
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methadone plasma levels were detected in MDR1 gene
normal dogs after oral administration of similar doses
of methadone [9]. Methadone is biotransformed mainly
by the cytochrome P-450 (CYP3A4) and in minor im-
portance, CYP2C8 and CYP2D6. Studies in man and
dogs, suggest that the multi-drug resistance (MDR1)
gene and P-glycoprotein (p-gp), enrolled in the protec-
tive mechanism of the body, play a role in the disposi-
tion of orally administered methadone [4,9]. All horses
in this study were genotipically normal for the MDR1
gene.
The oral methadone behavior demonstrated a
dose-dependent curve, inferring good absorption and
distribution when administered by oral route in horses,
without side effects. These results can be explained
similarly to what is seen in human beings. The pharma-
cokinetics of methadone is characterized by excellent
oral absorption and higher oral bioavailability (70-
100%), compared to morphine (26%). With long dura-
tion of action (6-8 hrs) and long elimination half-life
(20-24h), the therapeutic blood concentrations of me-
thadone for acute pain in people were reported to
range between 33 ng/ml and 59 ng/ml when an oral
dose of 0.1mg.kg -1 is used [2]. We obtained similar
dose-response curves although antinociception was not
evaluated.
CONCLUSIONS
In conclusion, methadone is absorbed when
orally administered in horses at doses of 0.1, 0.2, and
0.4mg/kg. It does not produce excitement, sedation,
nor undesirable side effects in healthy horses. Oral
administration of methadone may be considered safe
and a viable route for horses. Further studies are neces-
sary in order to establish clinical guidelines for oral
methadone as an alternative for pain management in
the horse. This study was conducted at the Louisiana
State University, School of Veterinary Medicine and
approved by the Louisiana State University Institutional
Animal Care and Use Committee.
SOURCES AND MANUFACTURERS
1Methadone. Methadone Hydrochloride  10 mg per mL –
Alpharma, Inc; Lincolnton, NC, EUA
2Agilent Technologies, Wilmington, Delaware, EUA.
3Agilent Technologies, Wilmington, Delaware, EUA.
Figure 1. Time (minutes) vs. concentration (ng/ml) showing the mean ± SD serum concentration curve of 3
doses of methadone (0.1, 0.2, 0.4mg/Kg) administered by oral route in horses.
*Significantly different from 0.2 and 0.4mg.kg-1.
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